EAC 2026 - Update in Allergy, Asthma & Immunology

Palm Beach, FL US
May 28, 2026 to May 31, 2026

The 2026 EAC activity will provide conference attendees with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma, and immunology.

In addition to a didactic review of relevant guidelines and recent clinical studies, the format will incorporate problem-based learning (PBL), uniquely designed to interface with lectures in context to the core issues relevant to the cases.

Through active discussion, learners will be challenged to formulate and demonstrate shared decision-making regarding diagnostic and treatment strategies for patients. Topics of discussion will include severe asthma, chronic spontaneous urticaria, atopic dermatitis, CRSwNP and AERD, biologics for allergic disease, anaphylaxis, allergen immunotherapy, food allergy, mast cell disorders, and HAE.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Eastern Allergy Conference (EAC).  The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 17 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 17 contact hours.

Commercial Support
This activity is supported in part by an independent medical education grant from Biocryst.

Target Audience

Allergist-Immunologists in clinical practice
Fellows in Training (FIT) A-I programs
Primary care providers who care for patients with allergic disease
Allied health professionals in the field of allergy-immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Treat severe and difficult-to-control asthma in accordance with the most updated guideline-based approach
  • Manage adverse reactions to allergen immunotherapy treatment for respiratory allergies
  • Outline an approach to the use of biologics for allergic diseases, including asthma, CRSwNP, atopic dermatitis, and CSU
  • Diagnose and manage CRSwNP and AERD
  • Educate patients regarding treatment options for antihistamine-resistant chronic urticaria
  • Discuss treatment options for moderate/severe atopic dermatitis
  • Diagnose and manage hereditary angioedema
  • Implement food allergy prevention measures
  • Diagnose and manage drug allergy
  • Diagnose and manage mast cell disorders
  • Discuss options in rescue inhaler approaches
  • Implement improvements in practice management
  • Demonstrate competence in performing shared decision-making for diagnostic and treatment choices in patient care
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 17.00 AMA PRA Category 1 Credit™
  • 17.00 Attendance
  • 17.00 CBRN
Course opens: 
05/28/2026
Course expires: 
12/31/2026
Event starts: 
05/28/2026 - 3:20pm CDT
Event ends: 
05/31/2026 - 11:30am CDT
Add to calendar: 
Rating: 
0

EAC 2026 Program
May 28-31, 2026
The Breakers, Palm Beach FL

Thursday, May 28, 2026

3:20 - 3:50 PM            Defining and Managing Preschool Asthma, Leonard Bacharier, MD

3:50 - 5:00 PM            PBL: Introduction of High-Risk Foods in a 7-month-old Infant, Don Bukstein, MD, Ray Davis, MD, J. Allen Meadows, MD, Marcus Shaker, MD

5:00 - 5:30 PM            Food Allergy Prevention and Rescue Refeeding in 2026, Marcus Shaker, MD

5:30 - 6:00 PM            The UCLA and McMaster Studies: Should I Be Worried About Allergy Risk in 2026?, Don Bukstein, MD, Marcus Shaker, MD

6:00 - 6:30 PM            Perioperative Anaphylaxis, Kimberly Blumenthal, MD, MSc

6:30 - 6:40 PM            Panel Discussion: Q & A

Friday, May 29, 2026

7:45 - 8:15 AM            Monoclonals for Allergic Disease, Dennis Ledford, MD

8:15 - 8:45 AM            Genetic Testing in IEI - Who, When, and How to Interpret, Jolan Walter, MD

8:45 - 8:55 AM            Panel Discussion: Q & A

8:55 - 10:00 AM          PBL: A 31-year-old Female with Recurrent Swelling Episodes, Don Bukstein, MD, Ray Davis, MD, Maeve O'Connor, MD, Russell Settipane MD, Marcus Shaker, MD

10:00 - 10:45 AM        Coffee Break - Visit Exhibits and Posters (Not for CME)

10:45 - 11:15 AM        Advanced Treatment Options in HAE, Aleena Banerji, MD

11:15 - 11:45 AM        Evaluation and Management of Intermittent Abdominal Pain and Bloating, Brian Lacy, MD

11:45 AM - 12:15 PM  CSU Biomarkers and Advanced Treatments, Jonathan Bernstein, MD

12:15 - 12:30 PM        Panel Discussion: Q & A

1:25 - 1:55 PM            Evaluating Beta-lactam Allergy, Kimberly Blumenthal, MD, MSc

1:55 - 2:25 PM            Immediate Hypersensitivity Testing for Drug Allergies, Aleena Banerji, MD

2:25 - 3:00 PM            How to Evaluate and Treat Mast Cell Disorders, Cem Akin, MD

3:00 - 3:15 PM            Panel Discussion: Q & A

Saturday, May 30, 2026

7:45 - 8:10 AM            Debate: Pro-MCAS Referrals Should Be Screened, Cem Akin, MD

8:10 - 8:35 AM            Debate: Con-MCAS Referrals Should (Not) Be Screened, Jonathan Bernstein, MD

8:35 - 8:45 AM            Panel Discussion: Q & A

8:45 - 10:00 AM          PBL: A 47-year-old Woman with Nasal Polyps, Asthma, and AERD, Michael Blaiss, MD, Don Bukstein, MD, Ray Davis, MD, Marcus Shaker, MD, Dana Wallace, MD

10:00 - 10:45 AM        Coffee Break - Visit Exhibits and Posters (Not for CME)

10:45 - 11:00 AM        Who is at High Risk for Nasal Polyp Recurrence?, Russell Settipane, MD

11:00 - 11:20 AM        Is Aspirin Therapy Still Relevant to the Management of AERD?, John Bosso, MD

 11:20 - 11:50 AM       Evaluation of Comorbidities Associated with Chronic Rhinosinusitis, Anju Peters, MD

11:50 AM - 12:20 PM  Throat Mucus: Differential Diagnosis and Management, Joseph Han, MD

12:20 - 12:35 PM        Panel Discussion: Q & A

1:30 - 2:00 PM            Long-term Management of Biologics in Asthma, Alan Baptist, MD

2:00 - 2:25 PM            Debate: ICS/SAA is the Preferred Quick-Reliever, Juan Carlos Cardet, MD

2:25 - 2:50 PM            Debate: ICS/LABA is the Preferred Quick-Reliever, Alan Baptist, MD

2:50 - 3:00 PM            Panel Discussion: Q & A

Sunday, May 31, 2026

8:15 - 8:45 AM            When to Use AIR vs MART in Adults vs Children, Leonard Bacharier, MD

8:45 - 9:15 AM            Advanced Therapies for Atopic Dermatitis, Nicole Hawkins, MD

9:15 - 9:25 AM            Panel Discussion: Q & A

10:20 - 10:50 AM        AIT Adverse Reactions: Shared Decision Making After Large Local vs Systemic Reactions, Aarti Pandya, MD

10:50 - 11:20 AM        Social Media in A-I: Who is Succeeding and Why it Matters?, Payel Gupta, MD

11:20 - 11:30 AM        Panel Discussion: Q & A

The Breakers
1 South County Road
Palm Beach, FL 33480
United States

All relevant financial relationships with ineligible companies have been mitigated.

Cem Akin, MD – Speaker
Consultant - Blueprint Medicines, Cogent, Novartis
Researcher - Blueprint Medicines, Cogent, Telios

Leonard Bacharier, MD – Speaker
Advisor and Researcher - Sanofi/Regeneron, AstraZeneca
Consultant - Sanofi/Regeneron, AstraZeneca, Excellergy
Speaker - Sanofi/Regeneron

Aleena Banerji, MD – Speaker
Consultant - CSL, Biocryst, Pharvaris, Takeda, Astria, ADARx, Ionis, Intellia, Kalvista
Researcher - Intellia, Ionis, Astria

Alan Baptist, MD – Speaker
Advisor - Teva, GSK
Researcher - Teva, GSK, Genentech

Jonathan Bernstein, MD – Speaker
Researcher/Consultant - ADARx, Allergy therapeutics, Amgen, Apogee, Areteia, ARS, Astra Zeneca, Astria, Biocyrst, Blueprint Medicine, Celldex, Cogent, CSL Behring, Eli Lilly, Escient, Evommune, Genentech, GSK, Incyte, Intellia, Ionis, Jasper, Johnson and Johnson, Kalvista, Kenvue, Kymeria, Kyowa Kirin, Merck, Nektar, Novartis, Pharming, Pharvaris, Proctor and Gamble, Regeneron, Sanofi, Takeda/Shire, TEVA, Yuhan 
Speaker - Pharming, Kalvista, CSL Behring

Michael Blaiss, MD – Facilitator
Speaker – AstraZeneca, GSK, Novartis, Regeneron, Sanofi
Consultant – Bayer, Begin Health, GSK, Kenvue, Lilly, Nasus Pharma, Opella

Juan Carlos Cardet, MD – Speaker
Advisor - Apogee, AstraZeneca, Chiesi, Amgen, Genentech, GSK, Sanofi
Speaker - AstraZeneca, Amgen, Genentech, GSK, Sanofi

Ray Davis, MD – Facilitator
Consultant - Regeneron, Sanofi, Grifols, Kalvista, AstraZeneca, ARS
Speaker – ARS

William Greisner, MD – Planner, Moderator
Independent Contractor - GSK, Sanofi, AstraZeneca, Teva

Joseph Han, MD – Speaker
Advisor - Sanofi/Regeneron, AstraZeneca, GSK

Nicole Hawkins, MD – Speaker
Researcher - Pfizer, AbbVie

Brian Lacy, MD – Speaker
Consultant - GSK, Ferring
Researcher – Ironwood

Dennis Ledford, MD – Speaker
Consultant - AstraZeneca, Sanofi, Genentech

J. Allen Meadows, MD - Facilitator
Speaker    Advisor – Takeda
Consultant – Adherium

Maeve O’Connor, MD - Facilitator    
Advisor - Cogent, GSK, Regeneron, Methapharm, Intellia, Novartis
Speaker - GSK, Regeneron, CSL, Ionis, Pharming, Novartis, Kalvista, Sanofi
Consultant - Sanofi, Methapharm
Researcher -  Intellia, Takeda

Aarti Pandya, MD – Speaker
Speaker - Sanofi/Regeneron

Anju Peters, MD – Speaker
Consultant - AstraZeneca, Sanofi/Regeneron, Eli Lilly, GSK, Chiesi, Novartis
Independent Contractor – AstraZeneca
Researcher - AstraZeneca, Sanofi/Regeneron, Eli Lilly

Russell Settipane, MD – Speaker, Moderator, Planner, Reviewer
Advisor - AstraZeneca, BioCryst, Celldex, GSK, Novartis
Independent Contractor - AstraZeneca, BioCryst, GSK, Regeneron
Speaker - Amgen, ARS, AstraZeneca, Genentech, GSK, Grifols, Incyte, Novartis, Regeneron, Sanofi, Takeda

Dana Wallace, MD - Facilitator    
Advisor – Bryn, Genentech, ARS, Grifols, Kaleo

Jolan Walter, MD – Speaker
Advisor - X4-Pharmaceuticals, Takeda, Pharming, Chiesi, Adma-Biologicals, Grifols
Consultant - X4-Pharmaceuticals, Takeda, Pharming, Chiesi, Adma-Biologicals, Grifols
Researcher - Orca Bio, Grifols, Takeda, Octapharma, X4-Pharmaceuticals
Speaker - Pharming, Takeda

The following have no relevant financial relationships with ineligible companies to disclose:
Joseph Bellanti, MD – Planner
Kimberly Blumenthal, MD, MSc – Speaker
John Bosso, MD – Speaker
Don Bukstein, MD – Speaker
William Corrao, MD – Planner, Moderator
Jill Courcier – Coordinator
Sandra Gawchik, MD – Planner, Moderator
Payel Gupta, MD – Speaker
Katelyn Keedy, RN – Planner
Ginny Loiselle – Coordinator
Robert Settipane, MD – Planner, Moderator, Reviewer
Marcus Shaker, MD – Speaker

Available Credit

  • 17.00 AMA PRA Category 1 Credit™
  • 17.00 Attendance
  • 17.00 CBRN
Please login or create an account to take this course.